1350652-35-5 Usage
Heterocyclic compound
Unique structure containing nitrogen atoms The compound has a six-membered ring structure with nitrogen atoms in its core, making it a heterocyclic compound.
Six-membered ring structure
Pyrrolo[3,4-c]pyrazole The core structure of the compound is a six-membered ring containing two nitrogen atoms, which is characteristic of the pyrrolo[3,4-c]pyrazole system.
Potential applications
Pharmaceutical and agrochemical industries Due to its interesting pharmacological and biological properties, 1-Phenyl-1,4,5,6-tetrahydro-pyrrolo[3,4-c]pyrazole can be used in the development of drugs and agrochemicals.
Synthesis of biologically active compounds
Building block for new drugs 1-Phenyl-1,4,5,6-tetrahydro-pyrrolo[3,4-c]pyrazole can be used as a starting material or intermediate in the synthesis of various biologically active compounds, potentially leading to the development of new drugs.
Valuable intermediate
Organic synthesis and drug discovery The chemical structure and properties of 1-Phenyl-1,4,5,6-tetrahydro-pyrrolo[3,4-c]pyrazole make it a valuable intermediate for use in organic synthesis and drug discovery processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1350652-35-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,0,6,5 and 2 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1350652-35:
(9*1)+(8*3)+(7*5)+(6*0)+(5*6)+(4*5)+(3*2)+(2*3)+(1*5)=135
135 % 10 = 5
So 1350652-35-5 is a valid CAS Registry Number.
1350652-35-5Relevant academic research and scientific papers
SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES
-
Page/Page column 57, (2011/12/04)
The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
